One-Time Gains Mask Volume Decline; Near-Term Recovery Uncertain
Reported profit surged 258%, but ₹50–60 Cr in inventory and forex gains—13% of EBITDA—are temporary. Strip them and underlying volumes are down 12% quarter-on-quarter, revealing softness the market is already pricing in.
₹155 Cr
+258% YoY
₹50–60 Cr
13–16% of EBITDA; temporary
~₹325–335 Cr
Ex gains; core run-rate
−12%
QoQ; −17% energy, −7% non-energy
On the headline, AARTI's Q1 looks exceptional: net profit up 258% year-on-year to ₹155 crore. But the company offered no guidance upgrade on the call, and management's cautious tone hints at why. Nearly ₹50–60 crore—roughly 13–16% of reported EBITDA—came from inventory markups and forex volatility rather than operational improvement. Strip these one-time items and core EBITDA lands at ₹325–335 crore, a far less impressive picture. The quarter was held up on temporary gains while volumes contracted sharply.
Where the profit—and the pressure—came from
Revenue of ₹2,387 crore (+42.5% year-on-year, +8.2% quarter-on-quarter) was driven almost entirely by raw material cost pass-through, not volume. Management disclosed that energy segment volumes fell 17% quarter-on-quarter and non-energy 7%, for a blended volume decline of 12%. Yet revenues grew. That disconnect is the quarter in a nutshell: pricing and raw material pass-through masked an underlying business losing momentum.
Net profit at ₹155 crore looked sensational until the call disclosed that ₹50–60 crore of the quarter's gains came from inventory holdings marked higher as raw material prices spiked in early April, and from forex volatility—rupee swung between ₹92–97 across the quarter. Adjusted for these items, the organic profit base is roughly ₹100 crore, a 30–35% year-on-year lift, not 258%.
The FX and inventory gains are difficult to estimate correctly, but I think the impact could be anywhere in the range of INR 50 crore to INR 60 crores. But it is difficult to quantify that precisely because within the quarter, we saw significant volatility.
Management's claims vs. what the numbers show
Revenue ₹2,627 Cr, 41% YoY growth
Delivered ₹2,387 Cr, 42.5% YoY—call figure overstates magnitude by ~₹240 Cr
Overstated
PAT ₹155 Cr, 260% YoY; EBITDA ₹385 Cr, 79% YoY
Delivered PAT/EBITDA matched stated figures. But ₹50–60 Cr (13–16%) from one-time gains; organic base ~₹100 Cr PAT, ₹325–335 Cr EBITDA
Supported, but quality compressed
Volume declines offset by pricing and capacity expansion
Volume drop is material and real; offset by raw material pass-through pricing, not new volume or productivity gains
Partial—growth is price-driven, not volume-driven
West Asia exposure reduced 15% → 2%; volumes redirected to U.S., Africa, Europe with strong demand
Diversion confirmed, but replacement markets lower-margin; energy segment hit hardest (−17% QoQ volumes)
Acknowledged but risk downplayed
What changed on this call
The quarter brought three major shifts. First, West Asia market access halted. The region accounted for ~15% of revenues (primarily fuel additives), but geopolitical crisis forced management to reduce exposure to just 2%. Volumes were redirected to the U.S., Africa, and Europe—markets that exist, but at lower margins and with longer shipping times. A ₹340+ crore-per-annum revenue base has been temporarily lost, and recovery timeline is uncertain.
Second, Zone IV execution delays materialized. The 5-chemistry multipurpose plant was targeted for FY27 full commissioning but has slipped 3–6 months due to labour shortages (LPG issues, elections, monsoon in March–May). Management now expects the multipurpose plant to commission in August–September 2026, with phased block commissioning through FY27–29 instead of all at once. Equipment is 97% erected and piping 85% complete, but the timeline risk is material for FY28 EBITDA targets.
Third, Augene JV commissioning is now expected in Q2 FY27 (July–September), with first material ramp-up visible by Q4. Pilot qualifications with target customers are complete, and raw material sales have begun. The 50–50 JV with Superform targets ₹300–400 crore steady-state revenue in amines derivatives, with meaningful PAT contribution 2–4 quarters after commissioning. This is a real catalyst, but execution-dependent.
On the positive side, fuel additives capacity expanded to 360 KTPA and is ramping to high utilisation as Q2 demand picks up. A backward-integration contract (customer unnamed, likely a global producer) is in project execution phase with commissioning targeted for September–October 2027. These are tangible, multi-year moats being built.
The bull case and the bear case
Long-term JV pipeline (Augene, Zone IV, fuel additives, backward integration) backed by capex and customer traction
FY27 capex ₹700–800 Cr on track; FY28 EBITDA ₹1,800 Cr guidance maintained (no cuts, all-in commitment)
Fuel additives capacity expansion (290 KTPA → 360 KTPA) ramping to high utilisation; gasoline-naphtha spreads supportive
Q1 reported PAT (+258% YoY) heavily propped by ₹50–60 Cr one-time gains; organic base ~₹100 Cr (+30–35% YoY)
Volume contraction 12% QoQ despite 42.5% revenue YoY—growth is pricing/pass-through, not volume
West Asia market lost (15% → 2% revenue); diversion to lower-margin geographies; recovery timeline uncertain
Zone IV delayed 3–6 months; phased commissioning FY27–29 vs originally FY27; execution risk on FY28 ramp
Working capital expanded, debt and finance costs rose; deleveraging target at risk if raw material inflation persists
Competitive intensity rising in fuel additives (2–3 India/China entrants); margin compression risk
Management tone cautious; deferred on FY28 guidance updates; deflected on EBITDA trajectory when pressed
Risks, ranked by how much they should concern a holder
Earnings quality / one-time gain dependency
High₹50–60 Cr (13–16% of EBITDA) from inventory and forex volatility is temporary. Next quarter's organic EBITDA will be ₹325–335 Cr base without gains. If volumes don't recover, Q2 profit will compress 25–35%, disappointing the street.
West Asia market disruption and re-entry uncertainty
High15% of revenues (₹340+ Cr annually) halted. Diversion to U.S., Africa, Europe limits pricing power. Geopolitical timeline unknown; Middle East recovery may take 6–18 months. Until then, margin drag persists.
Zone IV execution delays and phased ramp impact
Medium-HighAlready 3–6 months behind. Commissioning now Aug–Sept 2026 (tight), with phased block roll-out through FY27–29 instead of FY27. Delays push product revenue and margin uplift into later periods. FY28 EBITDA ₹1,800 Cr target assumes timely ramp.
Volume recovery uncertain amid macro headwinds
Medium−12% volumes QoQ despite +42.5% revenue (raw material pass-through). Management expects Q2 recovery, but polymers demand, agrochemical customer purchasing, and dyes destocking remain under pressure. Proof of recovery is critical.
Working capital inflation and debt rising
MediumRaw material inflation and export volumes expanded WC requirements. Debt and finance costs rose in Q1. Deleveraging target is at risk if raw material prices stay elevated or volumes remain soft. Cash conversion deteriorating.
Competitive intensity in fuel additives escalating
Medium2–3 India and 2–3 China competitors now in the market. Management maintains cost leadership and product differentiation, but margin compression and customer concentration risk if pricing pressure mounts.
JV ramp-up execution (Augene, RESL, backward integration)
MediumFY28 EBITDA ₹1,800 Cr includes Augene contribution. Commercial batch requalification still required post-commissioning. Ramp delays or underperformance vs. ₹300–400 Cr target could miss FY28 guidance.
How the street is positioned, and what the market verdict is
The stock price at ₹534.1 is just 1.4% below its all-time high of ₹541.7, and 57.99% above its 52-week low. The post-result reaction was muted: day 1 pop of +1.85% (delivery 46.7%), then faded to +0.32% by day 3 and +4.37% by day 5. That fade is telling—the market initially priced in the headline profit growth, then questioned the quality as the earnings call transcript circulated and the one-time gains came into focus. RSI at 73.2 is in overbought territory, suggesting limited upside and high vulnerability to disappointment.
Ownership shifted marginally in Q1: FII trimmed from 7.38% to 6.99% (−0.39 percentage points), while DII added from 20.12% to 21.11% (+0.99 percentage points). Promoters held steady at 41.82% (−0.27 percentage points). The FII trimming is significant—global investors are cautious despite headline growth, likely due to earnings quality concerns and the geopolitical uncertainty around West Asia. DII support suggests domestic confidence, but it's not enough to offset foreign selling.
The market's own verdict is clear: headline growth is real, but sustainability is in question. The stock is priced for near-term optimism (at all-time high) on long-term catalysts, but the near-term execution risk (Q2 volume recovery, one-time gain fade, West Asia disruption) is high. FII pullback signals skepticism on valuation. A miss in Q2 volumes could trigger a sharp pullback from current levels.
What to watch next
1 · Q2 FY27 organic EBITDA run-rate and volume recovery
Management guided for volume pickup in Q2 as raw material softens and polymer demand recovers. The key: does adjusted EBITDA (ex one-time gains) tick up or drop from Q1's ₹325–335 Cr base? If it drops below ₹300 Cr on volume miss, the thesis breaks.
2 · Zone IV multipurpose plant (MPP) commissioning and first product revenue
Expected August–September 2026. Commercial batch requalification begins post-commissioning. Need to see whether first products hit revenue by Q4 or slip further. Also: what is the actual yield/margin profile vs. management's ₹1,800 Cr FY28 EBITDA assumption?
3 · Augene JV ramp-up and Q2 PAT consolidation visibility
Commissioning is on track for Q2 FY27. First material ramp should be visible in Q3–Q4. The question: does utilisation and pricing track toward ₹300–400 Cr steady-state revenue, or is uptake slower? PAT contribution impact expected 2–4 quarters out.
4 · Middle East market re-opening timeline and West Asia volume recovery
Geopolitical uncertainty is the wild card. Any news on cessation of disruptions or volume re-entry into Middle East markets would be a material catalyst. Until then, assume ₹340+ Cr-per-annum revenue base remains shut and margins remain pressured.
5 · Raw material price trajectory and working capital stabilisation
Raw material pass-through drove Q1 revenue growth. If crude/naphtha falls sharply, destocking risk and inventory losses could reverse Q1's gains. Raw material price stability (or further softening) is key to margin outlook and debt trajectory.
AARTI is executing a real, multi-year expansion strategy—Augene, Zone IV, fuel additives, backward integration. The long-term roadmap is credible and backed by capex deployment. But Q1 obscured the near-term reality: volumes are down 12% quarter-on-quarter, profit is propped up by ₹50–60 crore in one-time gains that won't repeat, and the West Asia market disruption has cost the company ₹340+ crore in annual revenue exposure.
This is a hold for existing shareholders. The fundamental question is whether management can ramp volumes fast enough to offset the fade of one-time gains and the drag from West Asia diversion. Q2 will answer that. For new buyers, the stock at all-time-high valuations (RSI 73, FII trimming) offers poor risk-reward. Wait for volume recovery confirmation in Q2 before adding.
The number to track from here is adjusted EBITDA (ex one-time gains). If Q2 adjusted EBITDA sustains or grows above ₹325–335 Cr, the thesis holds. If it falls below ₹300 Cr, the growth narrative breaks. Everything else—Zone IV, Augene, West Asia recovery—flows from near-term execution on volumes.
Margin growth masks volume declines; one-time gains inflate EBITDA
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade B
FY27 capex ₹700–800 Cr on track. Q1 delivered PAT matched guidance. But revenue figure discrepancy (call ₹2,627 Cr vs delivered ₹2,387 Cr, ~10% gap) and heavy reliance on one-time gains weaken track record.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered strong PAT growth (₹155 Cr, +258% YoY) but heavily propped by ₹50–60 Cr inventory/FX one-time gains. Underlying volume decline (−12% QoQ) and margin compression from high raw material and freight costs reveal softness. West Asia crisis reduced exposure from 15% to 2%, forcing redirection. Near-term recovery dependent on volume ramp, Q2 demand, and Middle East stabilisation. Long-term supported by Augene JV (₹300–400 Cr target), Zone IV (25–30 products by FY28), and fuel additives expansion, but execution risk is material.
₹2387 Cr
Revenue · +42.5% YoY₹155 Cr
Reported PAT · +258% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue 2,627 Cr, 41% YoY growth
OVERSTATEDDelivered revenue 2,387 Cr, 42.5% YoY growth
PAT 155 Cr, 260% YoY growth
METDelivered PAT 155 Cr, 258% YoY growth
EBITDA 385 Cr, 79% YoY; inventory/FX gains ₹50–60 Cr
OVERSTATEDIf gains are ₹50–60 Cr, core EBITDA ~₹325–335 Cr; quality compressed
Energy volumes down 17% QoQ, non-energy down 7% QoQ
MET12% overall volume decline QoQ is material softness vs delivered revenue +8.2% QoQ
West Asia exposure fell from 15% to 2%, volumes redirected
PartialImpact quantified but redirection efficacy unclear; offset sales loss with price, not new volume
Earnings quality
What changed since the last call
West Asia fuel additives market access halted
Downgrade15% revenue exposure to Middle East fell to 2% due to geopolitical crisis. Diversion to other markets limits pricing power and margin recovery.
Zone IV execution delayed 3–6 months
DowngradeLabour shortage (LPG issue), elections, monsoon triggered delays. MPP expected Aug '26 now; 5 chemistry blocks phased FY27–29 vs originally FY27. Impacts FY28 EBITDA ramp.
Capex intensity expected to reduce next year
UpgradeMajor expansion programs nearing completion; pivot to high-growth niche projects. FY27 ₹700–800 Cr capex will tail as Zone IV finishes.
Fuel additives portfolio broadening beyond MMA
Neutral3–5 new products in pipeline across fuel additives; 1–2 years to scale. Strategy to reduce single-product risk; execution timeline uncertain.
NCB chain margin recovery confirmed
UpgradeChina VAT suspension created pricing tailwind. Management notes improvement 'last quarter' and expects sustained benefit as global chemical overcapacity rationalises post-2028.
The Q&A
Analysts pressed hard on EBITDA trajectory sustainability (Aditya Khetan: ₹385 Cr EBITDA minus ₹50–60 Cr gains = ₹325–335 Cr core; path to ₹1,800 Cr FY28 unclear). Management deflected with 'volume growth will compensate' but did not commit. Rohit Nagraj questioned Zone IV impact on FY28 guidance; management said 'too early to revise, will update later.' Overall tone was cautious, non-committal on trajectory. Analysts focused on quality and macro headwinds; management held firm on long-term roadmap.
Zone IV capex delays — Rohit Nagraj, 360 ONE Capital
PartialJVs (Augene, RESL) expected on time. 5 chemistry blocks delayed but phasing into FY27–29. Will update once units commission and ramp visible.
Inventory/FX gains quantification — Rohit Nagraj, 360 ONE Capital
AnsweredCombined ₹50–60 Cr possible. Difficult to quantify precisely due to monthly RM price volatility (April high, May-June correction, June-July restart). Timing of purchase vs placement supported EBITDA.
Energy market diversion and capacity — Arun Prasath, Avendus Spark
AnsweredMarket development phase still ongoing. Portfolio now balanced across U.S., Africa, Europe, Middle East, India. Can move volumes regionally. When Middle East opens, will add capacity utilization, not shift volume. Confidence high on demand side given strong gasoline-naphtha cracks.
Competitive intensity in fuel additives — Arun Prasath, Avendus Spark
AnsweredSignificant competition already exists. Strategy: new differentiated products, global supply chain, unique distribution. Cost leadership guaranteed (top decile). Multiple levers beyond price.
Augene JV steady-state revenue — Arun Prasath, Avendus Spark
AnsweredMaintaining ₹300–400 Cr range for now. Will refine once Q2 ramp complete and stabilised. Expected 1–2 years to decent utilisation. PAT consolidation starts Q2, meaningful difference 2–4 quarters out.
Gross margin decline despite one-time gains — Aditya Khetan, SMIFS Institutional Equities
AnsweredTwo factors: RM inflation (cyclical) and NCB chain China VAT removal (structural). Some reversal on RM, but VAT element may sustain. Portfolio-specific dynamics differ.
EBITDA trajectory and base business — Aditya Khetan, SMIFS Institutional Equities
PartialFX gain is accounting/volatility artifact. In future, if pricing stable throughout quarter, underlying business potential will show. Volume recovery should compensate for gain loss. Trajectory on track.
Price hike sustainability and volume outlook — Aditya Khetan, SMIFS Institutional Equities
Partial59% exports for the quarter. Exports expected up in Q2. Supply chain changing to longer-destination geographies (U.S., Americas). Revenue recognition timing linked to inco terms (DAP). But underlying volume trajectory solid.
Zone IV chlorotoluene execution issues — Viraj Vajratkar, Kotak AMC
AnsweredStrategy changed 1.5 years ago: 5 chemistry blocks now flexible (not just chlorotoluene). 97% equipment erected, 85% piping done. Challenge: manpower for piping/insulation. March–May labour shortage (LPG, elections, monsoon). Back to full capacity now. Commissioning FY27.
Augene JV end-markets and margins — Viraj Vajratkar, Kotak AMC
AnsweredTwo dominant end markets: coatings (larger, India-focused) and dyes. Profitability expected higher margin profile vs current portfolio. Exposure to different end market helpful for diversification.
MMA market strength and fungibility — Viraj Vajratkar, Kotak AMC
AnsweredMarket remains very strong globally, linked to end-market (gasoline/naphtha cracks). When Middle East opens, goal is to increase capacity utilisation, not shift volume. Pulling from all geographies to boost utilisation.
Fuel additives market and new products — Sanjesh Jain, ICICI Securities
PartialSpreads averaged $15–18/bbl globally, healthy. Will not name products at this stage. 3–5 products in pipeline. Broadening from MMA to multiproduct portfolio over 12 months.
Raw material destocking risk — Sanjesh Jain, ICICI Securities
AnsweredRisk always remains in crude-linked business. Mitigation: 7–15 days domestic RM inventory, 1–1.5 months import inventory. Strategies: forward booking, hedging. Risk actively managed but will always exist.
NCB chain margin recovery narrative — Sanjesh Jain, ICICI Securities
AnsweredDifferent chains have different stories. NCB recovered in last quarter (China VAT impact). DCB always decent margins. NT suppressed, working on rebalancing strategies. PDA weak (tech disadvantage). Objective: expand volume and margin across all chains.
Zone IV product approval and commercialisation — Sanjesh Jain, ICICI Securities
AnsweredTarget customers identified, pilot qualification done in most cases. Commercial batch requalification required post-commissioning. By FY28, 25–30 products target. FY27, 5–10 products expected.
NCB and nitration chain expansion — Archit Joshi, Nuvama Asset Management
AnsweredAssets capable of more volume. Minor debottlenecking being evaluated. Dominant end market: pharmaceuticals (paracetamol). Watching Indian consumption potential. Aggressive once domestic demand justifies capex.
Global chemical industry rationalisation and MMA spreads — Archit Joshi, Nuvama Asset Management
PartialDifficult to predict. Chemical industry turbulent 3–4 years post-COVID. Global rationalization ongoing (Europe, Northeast Asia, China slowdown). If continues, post-2028/2029 could see demand pickup, capacity tightness, margin restructuring. Hypothesis—need 2–3 years to validate.
Quarterly EBITDA run-rate sustainability — Abhijit Akella, KIE
PartialNot far away. Given ±15–20% monthly volatility, difficult to hazard guess. Volume growth could compensate for lost inventory gains. Near-term quarter outlook: volume gain offsets gain loss.
JV consolidation and FY28 EBITDA target — Abhijit Akella, KIE
PartialAugene EBITDA included in ₹1,800 Cr guidance (expected to contribute by then). Re Aarti not expected to contribute meaningfully before FY27–28. Reporting treatment to be determined.
Fuel additives capacity utilisation — Abhijit Akella, KIE
AnsweredRamping up as we speak. Might reach high utilisation levels this quarter. (Note: implies near-term pickup expected.)
Gross margin decline QoQ — Surya Narayan Patra, PhillipCapital India
PartialGross margin at quarterly level not reflective of steady-state. EBITDA % on track. Multiple factors: RM purchase timing, product placement timing, FX volatility within quarter, freight volatility, lower volume/higher opex in some cases. Not a structural decline.
MMA seasonality outlook — Surya Narayan Patra, PhillipCapital India
AnsweredFuel additives basket has seasonal weakness in winter (Oct–Dec). Cracks step down, demand softens. Prepared for winter downturn. Mitigation strategies for lean season under evaluation. Some seasonality expected.
Polymer volume decline — Surya Narayan Patra, PhillipCapital India
AnsweredLimited Middle East exposure in polymers. Q4 had bulk shipments to U.S. customers; Q1 shipments low as a result. Recovery expected Q2. Year-on-year growth still expected.
Energy segment geography mix — Tushar Raghatate, Omega Portfolio Advisors
PartialWell-balanced across geographies. Not tilted to one. QoQ volatility (one geo picks up significant share), but year-average balanced. Will not give exact split.
Voyage time impact on margin — Tushar Raghatate, Omega Portfolio Advisors
AnsweredNo direct margin impact. Impacts accounting: many sales on DAP terms, 2–3 month voyage time delays revenue recognition. Accounting artifact, not economic profit issue.
EBITDA margin new normal — Tushar Raghatate, Omega Portfolio Advisors
PartialDid not say EBITDA run rate maintained. Two factors: volume gain (confident and visible) and pricing/inventory (macro-dependent, uncertain). Geopolitical settlement timing and pricing change speed will determine margin path.
MMA addressable market size — Gagan Dixit, Elara Capital
DodgedWill not give number. Overall fuel additive market in millions of tons. Early market development journey; phases of customer adoption ongoing. Upper-side potential high but unrealistic to quantify. Trade flows dynamic.
MMA competitive advantages — Gagan Dixit, Elara Capital
PartialRecently expanded to 360 KTPA. Capacity for overall fuel additives block (not single product). Will stabilise utilisation over 12 months, then decide on further expansion. No restrictions on future capacity growth.
End-market demand visibility and capex allocation — Gagan Dixit, Elara Capital
AnsweredMost end markets showing steady demand. Agro stable, polymers strong (EVs, automotive), pharma robust, dyes/pigments soft. Selection based on ability to deliver customer value and return on capital. Forward-looking molecules (battery, defense) driven by differentiation and scale potential.
Forex gain driver and Q2 outlook — Ojas Sawant, Haitong Securities
AnsweredVolatility in Q4 and Q1 on currencies. INR92–97 range in quarter. Sourced imported material high, rupee appreciated in April, squared up at lower rate (gain). Exports initially at lower rates vs current. Operational element with mark-to-market. Going forward, difficult to commit to gain/loss due to macro factors.
Ethylene crackers closure impact — Prateek Dugar, Intelsense
AnsweredProducts part of strategic focus. Most contracts have ethylene price pass-through (quarterly or monthly). Margin profile secured. Volatility near-term but long-term robust. Closures in Japan/Korea don't impact India/China/Europe production zones for these products.
SABIC backward integration project — Archit Joshi, Nuvama Asset Management
AnsweredDo not name customer. Long-term contract announced last quarter. In project execution phase. Civil/building work ongoing. Commissioning expected Sept–Oct 2027. (Note: project execution lagging slightly given call date was July 31, 2026.)
Guidance
No explicit FY27 revenue target quantified this call
LowManagement deferred on specific FY27 revenue forecasts. Implied growth from EBITDA targets suggests mid-teens growth assumed.
EBITDA margin sustenance subject to volume recovery and RM price stability
MediumManagement noted one-time gains (₹50–60 Cr) temporary. Underlying EBITDA margin ~13.6% (normalised). Expansion possible if volumes ramp and RM stabilises.
FY27 capex ₹700–800 Cr on track; ₹180 Cr deployed in Q1
HighAt current burn rate (₹180 Cr per quarter), ₹700–800 Cr achievable over full year. Major programs (Zone IV, Augene, RESL, MPP) progressing.
Capex intensity reducing from FY28 as expansion programs near completion
HighOnce Zone IV phases complete, pivot to high-growth, high-return niche projects. Capital efficiency improvement expected.
Risks the call surfaced
Project execution delays
MediumZone IV 5 chemistry blocks delayed by labour shortage and geopolitical issues. March–May labour constraints (LPG shortage, elections, monsoon). Phased commissioning FY27–FY29 vs originally FY27. MPP Aug 2026 timeline tight.
Geopolitical supply disruption
HighMiddle East geopolitical tension temporarily halted exports to region. 15% of revenues to West Asia fell to 2% in Q1. Volumes redirected to U.S., Africa, Europe, but at lower margins. Duration of crisis uncertain; recovery timeline unknown.
Volume and demand softness
MediumDespite 42.5% YoY revenue growth (driven by raw material pass-through), absolute volumes contracted sharply QoQ. Energy segment hit by West Asia disruption; non-energy by customer purchasing delays (high RM environment) and bulk Q4 shipments pulling forward.
Earnings quality (one-time gains)
HighEBITDA ₹385 Cr boosted by ₹50–60 Cr inventory gains and forex benefits from rupee volatility (INR92–97 range in quarter). Strip gains and core EBITDA ~₹325–335 Cr, well below stated ₹385 Cr. Gains temporary and non-recurring.
Competitive intensity
MediumFuel additives market ('market development phase') now seeing competitor entry from Indian and Chinese players. Management maintains market leadership but competitive pressure mounting. Differentiation via products, supply chain, cost structure required but not assured.
Working capital stress
MediumHigher feedstock prices and increased export volumes expanded working capital requirements in Q1. Debt levels and finance costs rose to support WC needs. Deleveraging target at risk if WC inflation persists.
JV ramp-up and integration risk
MediumAugene JV (amines) expected to commission Q2 FY27 with ₹300–400 Cr steady-state revenue. RESL (plastic recycling) H2 FY27. FY28 EBITDA ₹1,800 Cr includes Augene contribution. Execution delays, low ramp-up, or market softer-than-expected could miss targets.
Management
Score 6/10. Transparent on challenges (Middle East, volume declines, one-time gains) but evasive on forward commitments. Withheld product names, market size, exact geo splits, customer names. Candid on execution delays and RM volatility. Communication clarity medium. Zone IV delayed 3–6 months (execution challenge). FY27 capex ₹700–800 Cr on track. ₹1,800 Cr FY28 EBITDA repeated but not upgraded. Q1 delivered mixed results: PAT target met but driven by one-time gains; volumes declined despite revenue growth. Track record: maintained prior guidance, no cuts.
1 · Q2 FY27
Volume recovery as polymer demand picks up; seasonality headwinds in MMA offset by other segments
2 · Aug–Sept 2026
Zone IV MPP commissioning; first product expected, commercial batch requalification begins
3 · Q2 FY27
Augene JV ramp-up visible in PAT consolidation (50–50 JV); first revenue recognition expected
Long-term supported by Augene JV (₹300–400 Cr target), Zone IV (25–30 products by FY28), and fuel additives expansion, but execution risk is material.
Aarti Industries Q1: PAT triples to ₹155 Cr on 42% revenue jump, margins expand
PAT +257.9% YoY · revenue +42.4% · margins expanding
₹2,387 Cr
+42.4% YoY
₹155 Cr
+257.9% YoY
6.49%
+3.9pp YoY
₹4.27
Aarti Industries delivered a sharp Q1 FY27 recovery. Consolidated revenue from operations rose 42% YoY to ₹2,387 Cr (up 8% QoQ), and net profit more than tripled to ₹155 Cr from ₹43 Cr a year ago, also up 13% sequentially from ₹137 Cr. On a standalone basis PAT was ₹144 Cr on ₹2,241 Cr revenue. The magnitude of the YoY jump is amplified by a depressed Q1 FY26 base, when net margin was just 2.31%; consolidated and standalone tell the same story (no material divergence in growth).
Q1 FY-2027 vs prior quarters
The print is a margin-expansion story riding operating leverage. Consolidated operating margin widened to 14.54% from 11.35% YoY (14.15% QoQ) and net margin to 5.89% from 2.31% (5.67% QoQ), as topline growth outpaced cost of materials while depreciation (₹124 Cr) and finance costs (₹83 Cr) stayed broadly steady. A ₹2 Cr exceptional gain from divesting subsidiary Shanti Intermediates is immaterial (<0.1% of revenue/PAT), so reported and underlying PAT growth are effectively identical (~258% raw, ~256% adjusted).
The stock went into the print at ₹480.2, up 2.7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated EPS ₹4.27 vs ₹1.19 YoY — standalone ₹3.98 vs ₹1.20
Management projects a challenging near-term due to geopolitical disruptions in the Middle East, which will fully impact the upcoming quarter, alongside significant raw material and freight cost pressures. FY27 capex is guided lower at INR 700-800 crore, reflecting a focus on capital efficiency and deleveraging, with ne
— This quarter: beat
Against its own outlook, the quarter reads as a beat: on the May concall management struck a cautious near-term tone, flagging Middle East geopolitical disruption that would "fully impact the upcoming quarter" plus raw-material and freight cost pressures — yet Q1 delivered strong growth and margin gains. Full-year FY27 street consensus sits near ₹8,290 Cr revenue / ₹419 Cr PAT; this quarter's ₹155 Cr PAT tracks ahead of that trajectory, though no brokerage-specific Q1 preview was available. One caveat cuts against guidance: consolidated net debt-equity rose to 0.80 from 0.72 QoQ (0.66 YoY), whereas management had guided net debt to decline alongside a lower ₹700-800 Cr FY27 capex.
W1
Middle East disruption management said would 'fully impact' the quarter — Q1 NPM still held at 5.89%; watch whether it lands in H2
W2
Net debt-equity at 0.80 vs guided decline; FY27 capex guided ₹700-800 Cr — verify deleveraging resumes
W3
Margin durability: OPM 14.54% vs 11.35% YoY — whether the recovery sustains against flagged RM/freight pressures
Clean digital PDF, in ₹ Cr; revenue shown as net of GST collected. Consolidated Q1FY27 carries a ₹2 Cr exceptional GAIN (SIPL divestment, note 7) — immaterial (<0.1% of rev/PAT). Q4FY26 column is balancing figures per auditor. Huge YoY PAT jump amplified by a depressed Q1FY26 base (NPM 2.31%).